|
**Overview**: Menopausal Screening Panel**Introduction**: The Menopausal Screening Panel is a diagnostic tool designed to screen for menopausal status using serum samples. In India, natural menopause occurs at ~46-47 years (earlier in rural/low-SES due to malnutrition, multiparity), with perimenopause symptoms (hot flushes, irregular bleeding, mood changes) affecting ~70-80 percent of women, often under-managed leading to osteoporosis or CVD risk. High morbidity from under-testing in rural/low-SES women with vasomotor symptoms or irregular cycles, limited endocrine labs, delayed HRT or lifestyle advice leading to bone loss or cardiovascular events. Per endocrinology practices aligned with ICMR, Endocrine Society of India, and Indian Menopause Society guidelines, the test employs immunoassay for FSH, LH, estradiol, and progesterone over 1-2 days with high accuracy, valuable for confirming menopausal transition (elevated FSH >30 IU/L, low estradiol). This diagnostic falls under hormonal screening and targets women >45 years with irregular cycles or symptoms, addressing accurate detection to guide HRT, bisphosphonates, or calcium/vitamin D. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise menopausal assessment and reducing long-term complications. Its serum-based approach ensures reliable gonadotropin/estrogen measurement.**Other Names**: Menopause Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: FSH-based menopausal screening standard; in India, used in menopause clinics.**Purpose**: The test assesses 4 parameters including FSH to guide menopausal status screening, confirm transition, inform HRT.**Test Parameters**: 1. FSH, 2. LH, 3. Estradiol, 4. Progesterone.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report irregular cycles or hot flushes.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on menstrual history, vasomotor symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated menopause including osteoporosis, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or HRT use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High FSH/low estradiol confirms menopause, necessitating specialist input.**Specialist Consultation**: Gynecologists or endocrinologists should be consulted for management.**Additional Supporting Tests**: AMH, bone density for confirmation.**Test Limitations**: FSH variable in perimenopause; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Menopause Studies India 2023. |
